YZYujun Zhang

Yujun Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yujun Zhang has a total of 104 co-authors. Here are the top co-authors by number of shared publications:

  • Wensheng Zhang

    Sichuan University

    13 shared publications
  • Jin Liu

    Department of Anaesthesiology, West China Hospital, Sichuan University, Chengdu, China; Laboratory of Anaesthesia and Critical Care Medicine, National-Local Joint Engineering Research Centre of Translational Medicine of Anaesthesiology, West China Hospital, Sichuan University, Chengdu, China

    6 shared publications
  • Jun Yang

    Laboratory of Anesthesia and Critical Care Medicine, Translational Neuroscience Center, West China Hospital Sichuan University Chengdu China

    6 shared publications
  • Jin Liu

    Department of Anesthesiology, West China Hospital, Sichuan University, Chengdu, China

    5 shared publications
  • Deying Gong

    Department of Anesthesiology, Laboratory of Anesthesia and Critical Care Medicine, Translational Neuroscience Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China

    4 shared publications
  • Yi Kang

    Department of Anesthesiology, Laboratory of Anesthesia and Critical Care Medicine, Translational Neuroscience Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China

    4 shared publications

Latest Publications

  • Open Access

    Anesthesia Management of Severe Hypoxemia During Total Arch Replacement for Acute Aortic Dissection: A Case Report

    by Liu Qian, Haibei Liu, Yujun Zhang

    Background: Acute aortic dissection poses a life-threatening condition that typically necessitates immediate surgical intervention, such as total arch replacement. However, hypoxemia is a severe complication in such surgeries, potentially resulting in organ dysfunction, prolonged hospital stays, and even mortality. Hypoxemia presents significant challenges to anesthesiologists. Through this case, we can enhance our comprehension of anesthetic management for total arch replacement. Case presentation: A 43-year-old man with acute type A aortic dissection underwent total arch replacement. After a smooth surgery, severe hypoxemia occurred during weaning off cardiopulmonary bypass. Initial interventions, including airway suction and recruitment maneuvers, failed to improve oxygenation. Further investigations found left lung atelectasis and pleural effusion on transesophageal echocardiography, with minimal improvement after drainage. Fiberoptic bronchoscopy revealed extensive tenacious secretions occluding the airways. Conventional suctioning was ineffective due to high sputum viscosity. Ultimately, techniques including pulmonary lavage, bronchoscopic suctioning, and repeated lung recruitment controlled the refractory hypoxemia. The patient recovered after treatment in the intensive care unit. Conclusions: It is worth noting that our case highlights the challenges posed by severe hypoxemia during total arch replacement surgery. The successful management of this complication underscores the importance of a multidisciplinary approach and close monitoring during the perioperative period. Individualized anesthetic management plays a critical role in addressing severe hypoxemia during total arch replacement surgery.

  • Phase III clinical trial comparing the efficacy and safety of adamgammadex with sugammadex for reversal of rocuronium-induced neuromuscular block

    by Yujun Zhang, Yingying Jiang, Qian Lei, Chaoyu Li, Shu'AN Jin, Qin Wang, Yidan Huang, Yalan Li, Yi Hong, Shoushi Wang, et al.


  • Open Access

    Successful management of perilous perioperative hypoxia in a total arch replacement procedure: a case report

    by Liu Qian, Yujun Zhang, Haibei Liu

    Background: Profound hypoxemia during total arch replacement surgery demands prompt intervention. Aortic dissection patients are susceptible to serious pulmonary complications. Case presentation: We report a critical case of intraoperative hypoxemia in this context. Despite no existing pulmonary issues, oxygenation difficulties during cardiopulmonary bypass weaning led to challenging procedural halts. Strategies such as airway suction, lung recruitment, and protective ventilation proved inadequate to rectify the hypoxic state. Transesophageal echocardiography indicated left pleural effusion and atelectasis, with minimal improvement after drainage. Fiberoptic bronchoscopy identified significant tenacious secretions obstructing the airway and left main bronchus, with conventional suction ineffective. Ultimately, pulmonary lavage and bronchoscopic suction, combined with repeated lung recruitment, led to enhanced oxygenation. Conclusions: It is crucial to conduct dynamic preoperative respiratory evaluations, particularly in patients with aortic dissection. Such assessments can effectively anticipate and prevent postoperative lung complications.

  • Open Access

    Comparison of the Efficacy and Safety of Adamgammadex with Sugammadex for Reversal of Rocuronium-Induced Neuromuscular Block: Results of a Phase II Clinical Trial

    by Yingying Jiang, Yujun Zhang, Zhaoqiong Zhu, Yidan Huang, Dachun Zhou, Jingchen Liu, Chaoyu Li, Xiangdong Chen, Dingxin Kang, Shoushi Wang, et al.

    This current phase II clinical trial was to compare the effect and safety of adamgammadex, a new cyclodextrin-based selective relaxant binding agent, with sugammadex to reverse rocuronium-induced neuromuscular block. Patients were randomised to receive adamgammadex (4 or 6 mg kg−1) or sugammadex (2 mg kg−1, as a positive control group) at the reappearance of the second twitch (T2) in response to TOF stimulation. The standard safety data were collected. The 4 mg kg−1 (n = 16) and 6 mg kg−1 (n = 20) adamgammadex- and 2 mg kg−1 (n = 20) sugammadex-induced recovery time of TOF ratio to 0.9 were 2.3, 1.6, and 1.5 min, respectively (p = 0.49). The 4 mg kg −1 adamgammadex-induced median recovery time was longer than that of 2 mg kg−1 sugammadex (p = 0.01), and there was no difference between the 6 mg kg −1 adamgammadex group and 2 mg kg−1 sugammadex group (p = 0.32). Then, the number of patients who experienced adverse events (AEs) was 6, 11, and 14 for adamgammadex at 4, 6 mg kg−1 and sugammadex at 2 mg kg−1, respectively. The treatment emergent AEs that occurred more than twice were detailed as follows: incision site pain, hypotension, emesis, fever, throat pain, blood bilirubin increase, abnormal T-wave of ECG, dizziness, incision site swelling, postoperative fever, expectoration, and nausea. For drug-related AEs, the increased urine acetone bodies and first-degree atrioventricular block were observed in two patients from sugammadex group. Then, the previously reported AEs were not observed in this study, including anaphylaxis, haemorrhage, recurarization, abnormal basic vital signs, or lengthened QRS intervals and QT intervals. Adamgammadex was found to be effective for reversal of rocuronium-induced neuromuscular block as sugammadex.


  • Physicochemical and Colon Cancer Cell Inhibitory Properties of Theabrownins Prepared by Weak Alkali Oxidation of Tea Polyphenols

    by Yao Yuan, Yuying Bai, Yujun Zhang, Haifeng Wan, Yuxi Hu, Zhengqi Wu, Xiuting Li, Wei Song, Xiaoqiang Chen

    Existing studies on the biological activity of theabrownins are not based on their free state but on the complexes of theabrownins, polysaccharides, proteins, and flavonoids. In this study, theabrownins (TBs-C) were prepared by weak alkali oxidation of tea polyphenols. The ultraviolet-visible scanning spectrum of TBs-C showed two characteristic absorption peaks at 203 and 270 nm. The zeta potential of the TBs-C aqueous solution was negative, and the values varied from − 6.26 to -19.55 mV with a solution pH of 3–9. Storage conditions of pH 5.0–7.0 and around 25 °C were beneficial for the physical and chemical stability of the TBS-C solution. Cells were treated with series concentrations and examined by MTT, HE staining, PI immunofluorescence staining, flow cytometry, and real-time PCR to investigate the antiproliferative effect of TBs-C on human colon cancer HT-29 cells. The results showed that TBs-C, particularly at 500 µg/mL, inhibited cell growth. TBs-C induced HT-29 cell apoptosis, as confirmed by morphological changes, nucleus propidium iodide staining, and distributions of the cell cycle. The apoptotic mechanism may be due to the intracellular redox imbalance induced by TBs-C.


  • Open Access

    Designer self-assembling peptide nanofibers induce biomineralization of lidocaine for slow-release and prolonged analgesia

    by Fei Peng, Jing Liu, Yujun Zhang, Jing Fan, Deying Gong, Liu He, Wensheng Zhang, Feng Qiu


  • Adamgammadex in patients to reverse a moderate rocuronium‐induced neuromuscular block

    by Ying Ying Jiang, Yu Jun Zhang, Zhao Qiong Zhu, Yi Dan Huang, Da Chun Zhou, Jing Chen Liu, Chao Yu Li, Bin Liu, Wen Sheng Zhang

    Aims: The aim of this study was to investigate the effectiveness, safety and pharmacokinetics of adamgammadex in surgical patients.Methods: Forty‐eight patients aged 18–64 years old were randomized to receive adamgammadex (2, 4, 6, and 8 mg.kg−1) or placebo at a ratio of 10:2 for reversal of 0.6 mg.kg−1 rocuronium‐induced neuromuscular block. Neuromuscular function was monitored by TOF‐Watch® SX. When the T2 of train‐of‐four (TOF) reappeared at the end of surgery, patients received an intravenous administration of adamgammadex or placebo.Results: The recovery time of the TOF ratio to 0.9 decreased significantly from 39.3 [29.5, 50.2] minutes in the group that received placebo to 3.0 [2.3, 3.9] minutes, P < .0001; 2.1 [1.5, 3.0] minutes, P < .0001; 2.1 [1.8, 3.3] minutes, P < .0001; and 1.8 [1.5, 2.2] minutes, P < .0001 in the 2, 4, 6 and 8 mg.kg−1 adamgammadex groups, respectively. Then, adamgammadex also showed a shortened recovery time for the TOF ratio recovered to 0.8 and 0.7. Adamgammadex was well tolerated, and no cases of anaphylactic reactions, post‐operative bleeding, recurarization, abnormal basic vital signs and prolonged QT intervals were observed. The pharmacokinetics of adamgammadex in plasma increased in dose‐dependent manner. The 24‐hour cumulative fraction of adamgammadex in urine was 65–83%, and that of rocuronium was increased after using adamgammadex from 15% to about 25–30%.Conclusion: Adamgammadex was found to be effective for reversal of rocuronium‐induced neuromuscular block, and it was safe and well tolerated in patients.


  • The 14‐day repeated‐dose toxicity studies of a fixed‐dose combination, QXOH/levobupivacaine, via subcutaneous injection in mice

    by Peiwen Gao, Yujun Zhang, Chaoyi Deng, Deying Gong, Yi Kang, Jin Liu, Wensheng Zhang

    QXOH‐LB, a fixed‐dose combination (35 mM QXOH and 10 mM levobupivacaine) has been shown to induce a long duration of local anesthesia in animal efficacy testing, which indicates potential for postoperative pain management. In this study, we evaluated the potential toxicity of QXOH‐LB in NIH mice under the Guidance on the repeated‐dose toxicity published by the China Food and Drug Administration. Mice (n = 30 per sex per group) were subcutaneously injected 5, 10, 20 mg/kg QXOH‐LB, 5, 10, 20 mg/kg QXOH, and 5 mg/kg levobupivacaine (LB) once a day for 14 days with sacrifice of main study animals; remaining mice (n = 10 per sex per group) were monitored for an additional 4‐week recovery period. Mice in the 10 and 20 mg/kg QXOH, and 20 mg/kg QXOH‐LB died, which was considered due to excessive respiratory inhibition. The doses of 10 mg/kg QXOH‐LB and 5 mg/kg QXOH were well tolerated without any clinical signs of toxicity. Therefore, the no‐observed‐adverse‐effect level (NOAEL) of QXOH‐LB and QXOH was considered to be 10 and 5 mg/kg/day, respectively. In the dose range from 5 to 20 mg/kg, the exposure of QXOH and LB in QXOH‐LB was equal to each agent used alone at the same dose in NIH mice. There was no gender difference on exposure and no evidence of accumulation.


  • The 14‐day repeated‐dose toxicity study of a fixed‐dose combination, QXOH/levobupivacaine, via subcutaneous injection in beagle dogs

    by Jie Zhang, YuJun Zhang, Qinqin Yin, Jun Yang, Yi Kang, Deying Gong, Jin Liu, WenSheng Zhang

    QXOH‐Levobupivacaine (LB) is a fixed‐dose combination of 35‐mM QXOH and 10‐mM LB. It was developed for perioperative analgesia because of its long‐acting analgesic effect. The purpose of this study was to evaluate the potential toxicity of QXOH‐LB in beagle dogs in accordance with the Guidance on the repeated‐dose toxicity published by the China Food and Drug Administration. Groups of five male and five female beagle dogs received normal saline, QXOH‐LB (2, 4, and 8 mg/kg, calculated as QXOH), QXOH (2, 4, and 8 mg/kg), or LB (2 mg/kg, equals the concentration of LB in 8‐mg/kg QXOH‐LB group) at the volume of 1 mL/kg once per day for 14 days through subcutaneous injection. No mortality was observed. Dogs in the control group as well as animals treated with 2‐mg/kg QXOH or QXOH‐LB exhibited normal behaviors. Clinical signs of toxicity in dogs treated with 4 and 8 mg/kg of QXOH or QXOH‐LB included decreased activity, unsteady gait, jerks, tremors, vocalization, emesis, ataxia, lateral/sternal recumbency, deep/rapid respiration, and gasping. Additionally, neurological function was found to be affected by QXOH and QXOH‐LB at the doses of 4 and 8 mg/kg. All clinical signs were recovered within 24 h. The no‐observed‐adverse‐effect level of QXOH and QXOH‐LB was considered to be 2 mg/kg. Toxicokinetic data showed that exposure to QXOH and LB increased as QXOH‐LB doses were increased from 4 to 8 mg/kg. There was no evidence of drug accumulation or any effect of gender.


  • Open Access

    The preclinical pharmacological study on HX0969W, a novel water-soluble pro-drug of propofol, in rats

    by YuJun Zhang, YingYing Jiang, HaiYan Wang, Bin Wang, Jun Yang, Yi Kang, Jun Chen, Jin Liu, Wen-Sheng Zhang

    Background: Propofol is the most widely used intravenous sedative-hypnotic anesthetic in clinical practice. However, many serious side effects have been related to its lipid emulsion formulation. The pro-drug design approach was used to develop the water-soluble propofol, which could effectively resolve the limitations associated with the lipid emulsion formulation. Thus, the new water-soluble pro-drug of propofol, HX0969W, was designed and synthesized. The objective of this study was to conduct preclinical pharmacological studies on this novel water-soluble pro-drug of propofol.Methods: The assessment of the loss of the righting reflex (LoRR) was used for the pharmacodynamic study, and liquid chromatography-tandem mass spectrometry and high-performance liquid chromatography- fluorescence were used for the pharmacokinetic study.Results: The potency of HX0969W (ED50[95% CI], 46.49 [43.89–49.29] mg/kg) was similar to that of fospropofol disodium (43.66 [43.57–43.75] mg/kg), but was lower than that of propofol (4.82 [4.8–14.82] mg/kg). Administered with a dose of 2-fold ED50, propofol required a shorter time to cause LoRR than that of HX0969W and fospropofol. However, the LoRR duration was significantly longer in response to the administration of HX0969W and fospropofol disodium than that caused by propofol. In the pharmacokinetic study, the Cmaxof fospropofol was higher than that of HX0969W. HX0969W had a shorter mean residual time and a rapid clearance rate than that of fospropofol disodium. There was no significant difference between the Tmaxof the propofol whether it was released by HX0969W or fospropofol disodium; the Cmaxof propofol released by HX0969W was similar to that of propofol, which was higher than the propofol released by fospropofol disodium.